 |
 |
|
|
|
| Everolimus |
 |
| 40-O-(2-hydroxyethyl)-rapamycin |
 |
| 159351-69-6 |
 |
| Everolimus, a proliferation signal inhibitor, prevents allograft rejection in rodent and non-human primate models of allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated T cells which is driven by T cell-specific interleukins, e.g. interleukin-2 and interleukin-15. Everolimus inhibits an intracellular signaling pathway which is triggered upon binding of these T cell growth factors to their respective receptors, and which normally leads to cell proliferation. The blockage of this signal by everolimus leads to an arrest of the cells at the G1 stage of the cell cycle. |
 |
Form: solid powder
Color: white to off-white
Odor: none
Melting point/Melting range:
Danger of explosion: none
Solubility in / Miscibility with water: not soluble
Solvent content: none
Organic solvents: soluble in DMSO or methanol
|
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
